In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

For decades now, Google has been the unquestioned champion of search—our digital oracle, the first and last stop for every question, from “What’s the best pizza place near me?” to “How many protons ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Google is officially launching its AI-powered Search Live feature in the U.S. on Wednesday, which enables mobile users to get real-time information with their voice and phone camera. Previously ...

Multiple tests have suggested ChatGPT is using Google Search. Well, a new report seems to confirm ChatGPT is indeed using Google Search data. The details. OpenAI used SerpApi, an 8-year-old scraping ...

I am seeing numerous tests now that seem to prove that OpenAI's ChatGPT search feature is using Google Search's index or search results page to serve its own search results. First, Abhishek Iyer ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...